Drugs / APO010
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00437736 | Feb 2007 → Nov 2008 | cancer | Valerio Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03196947 | Jun 2017 → Jan 2020 | refractory plasma cell neoplasm | Allarity Therapeutics | Terminated | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-05-31 | Allarity Therapeutics | MPI’s spinout Oncology Venture’s second drug candidate in the clinic – First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug allarity.com ↗ |
| 2016-10-28 | Allarity Therapeutics | MPI – Scientific publication in the Danish Journal Best Practice describes APO010 and its DRP allarity.com ↗ |
| 2016-10-10 | Allarity Therapeutics | Poster on Immuno Oncology APO010 sensitivity for Multiple Myeloma presented at ESMO allarity.com ↗ |
| 2016-08-08 | Allarity Therapeutics | MPI – Cisplatin and APO010 abstracts selected by ESMO’s Scientific Committee for poster presentation on its annual congress allarity.com ↗ |
| 2016-03-10 | Allarity Therapeutics | First patient included in APO010 immuno-oncology screening trial by MPI’s spinout Oncology Venture allarity.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APO010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03196947 ↗ |
| Modality | Protein / enzyme biologic | “APO010 is a protein that by specific binding to its cognate Fas receptor on the cell surface induces apoptosis (programmed cell death).” NCT00437736 ↗ |
| Route | Intravenous | “APO010 administered by intravenous bolus injection once per week” NCT00437736 ↗ |